Moderna, Inc. $MRNA Shares Purchased by AXQ Capital LP

AXQ Capital LP increased its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 115.4% during the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 21,749 shares of the company’s stock after buying an additional 11,650 shares during the quarter. AXQ Capital LP’s holdings in Moderna were worth $562,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Telemark Asset Management LLC purchased a new stake in Moderna in the 3rd quarter valued at $12,915,000. NEOS Investment Management LLC boosted its position in shares of Moderna by 52.2% during the 3rd quarter. NEOS Investment Management LLC now owns 38,662 shares of the company’s stock valued at $999,000 after acquiring an additional 13,258 shares during the last quarter. GSA Capital Partners LLP grew its holdings in shares of Moderna by 216.3% in the third quarter. GSA Capital Partners LLP now owns 38,922 shares of the company’s stock valued at $1,005,000 after purchasing an additional 26,617 shares during the period. Fifth Third Bancorp grew its holdings in shares of Moderna by 52.9% in the third quarter. Fifth Third Bancorp now owns 32,088 shares of the company’s stock valued at $829,000 after purchasing an additional 11,108 shares during the period. Finally, State of New Jersey Common Pension Fund D increased its position in Moderna by 4.0% during the third quarter. State of New Jersey Common Pension Fund D now owns 124,082 shares of the company’s stock worth $3,205,000 after purchasing an additional 4,744 shares during the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Insiders Place Their Bets

In other Moderna news, Director Noubar Afeyan sold 23,853 shares of the business’s stock in a transaction dated Thursday, December 11th. The shares were sold at an average price of $29.48, for a total transaction of $703,186.44. Following the sale, the director directly owned 3,924 shares in the company, valued at $115,679.52. This represents a 85.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 10.90% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several equities analysts have weighed in on MRNA shares. Morgan Stanley set a $30.00 target price on shares of Moderna in a report on Monday, February 16th. Evercore set a $35.00 price target on shares of Moderna in a research report on Tuesday, February 17th. BMO Capital Markets upgraded Moderna from a “market perform” rating to a “buy” rating in a research report on Monday, January 12th. Wolfe Research reissued an “underperform” rating and set a $17.00 target price on shares of Moderna in a research note on Thursday, November 20th. Finally, Jefferies Financial Group reaffirmed a “hold” rating on shares of Moderna in a research note on Monday, January 5th. Two analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and five have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Reduce” and a consensus price target of $31.87.

Moderna Stock Up 0.5%

Moderna stock opened at $50.52 on Wednesday. The company has a market capitalization of $19.95 billion, a PE ratio of -6.95 and a beta of 1.32. The company has a debt-to-equity ratio of 0.07, a quick ratio of 3.22 and a current ratio of 3.29. Moderna, Inc. has a fifty-two week low of $22.28 and a fifty-two week high of $55.20. The firm has a 50 day moving average price of $39.84 and a 200 day moving average price of $30.83.

Moderna (NASDAQ:MRNA) last released its quarterly earnings results on Friday, February 13th. The company reported ($2.11) EPS for the quarter, topping the consensus estimate of ($2.79) by $0.68. The business had revenue of $678.00 million during the quarter, compared to analyst estimates of $611.14 million. Moderna had a negative return on equity of 30.15% and a negative net margin of 145.16%.The company’s quarterly revenue was down 33.2% on a year-over-year basis. During the same period last year, the business posted ($2.91) earnings per share. Research analysts expect that Moderna, Inc. will post -9.61 earnings per share for the current year.

Moderna Company Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.